

Amniotics presents positive preclinical data on stem cell treatment for chemotherapy-induced peripheral neuropathy at ICRBE 2022

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that an abstract with new promising preclinical data on the treatment of chemotherapy-induced peripheral neuropathy (CIPN) with mesenchymal stem cells (MSC) has been accepted for a poster presentation at the 16th International Conference on Regenerative Biology and Engineering (ICRBE) taking place on July 28-29 in Zurich, Switzerland.

The abstract, titled “Amniotic Fluid Mesenchymal Stem Cells Selected for Neural Specificity Ameliorates Chemotherapy Induced Hearing Loss and Pain Perception”, will be presented by Amniotic’s COO Jan Talts at ICRBE. Other authors include Kåre Engkilde, CEO of Amniotics. The presentation includes preclinical results showing that treatment with MSC selected for neural specificity (CogniStem™) have significant positive efficacy on chemotherapy-induced hearing loss and chemotherapy-induced neuropathic pain.

“The results show the potential wide usages of tissue specific/relevant mesenchymal stem cells from amniotic fluid as treatment in connection with cancer therapy and represent further validation of Amniotics platform and our therapeutic approach. We’re excited about the data presented and will now evaluate how to leverage on these findings,” says Jan Talts, COO at Amniotics.

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by anti-neoplastic agents, with a prevalence between 19 and 85 percent. Clinically, CIPN is a mostly sensory neuropathy leading to pain and to motor and autonomic changes. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors, especially because currently there is no single effective method of preventing CIPN. Hearing loss is the most common form of sensory impairment in humans and can be caused by ototoxic chemical compounds such as chemotherapy (platinum-based antineoplastic agents).

For more information please contact

Kåre Engkilde
VD, Amniotics AB
Phone: +46 (0) 723 27 85 20
Email: ke@amniotics.com
or
Jan Talts
COO, Amniotics AB
Phone: +46 (0) 723278530
Email: jt@amniotics.com

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has its headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com.

Attachments

[Amniotics presents positive preclinical data on stem cell treatment for chemotherapy-induced peripheral neuropathy at ICRBE 2022](#)